SCHEMBL5372995

SCHEMBL5372995

Clc1ccc(CSc2nsc(OCc3ccccc3)n2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 1/20 0.51
RAB9A P51151 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
MAPK1 P28482 1/20 0.49
L3MBTL1 Q9Y468 5/20 0.47
CYP1A2 P05177 4/20 0.47
CYP2C9 P11712 4/20 0.47
CYP2C19 P33261 4/20 0.47
PTGS1 P23219 1/20 0.47
PTGS2 P35354 1/20 0.47
CTSB P07858 1/20 0.46
NPSR1 Q6W5P4 3/20 0.45
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
METAP2 P50579 1/20 0.43
CYP2D6 P10635 3/20 0.42
TDP1 Q9NUW8 3/20 0.42
MAPT P10636 2/20 0.42
ALDH1A1 P00352 1/20 0.42
CYP3A4 P08684 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5378195 0.92 RAB9A (0.59) ALOX15RAB9ASMN1; SMN2L3MBTL1CYP1A2
SCHEMBL5388491 0.85 CTSB (0.50) ALOX15RAB9ASMN1; SMN2L3MBTL1CYP2C9
SCHEMBL5388607 0.83 RAB9A (0.52) ALOX15RAB9ASMN1; SMN2L3MBTL1CYP1A2
SCHEMBL4800890 0.80 RAB9A (0.49) ALOX15RAB9ASMN1; SMN2MAPK1L3MBTL1
SCHEMBL5381773 0.80 MAPK1 (0.44) ALOX15RAB9ASMN1; SMN2MAPK1L3MBTL1
SCHEMBL5381872 0.80 L3MBTL1 (0.56) SMN1; SMN2MAPK1L3MBTL1CYP1A2CYP2C9
SCHEMBL5422577 0.79 SMN1; SMN2 (0.42) ALOX15RAB9ASMN1; SMN2L3MBTL1CYP1A2
SCHEMBL5381470 0.77 RAB9A (0.48) ALOX15RAB9ASMN1; SMN2CYP1A2NPSR1
SCHEMBL5377736 0.76 LMNA (0.47) ALOX15RAB9ASMN1; SMN2MAPK1L3MBTL1
SCHEMBL5375842 0.76 L3MBTL1 (0.44) ALOX15RAB9ASMN1; SMN2MAPK1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070293510-A1 Thiadiazole compounds and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED ( A JAPANESE CORPORATION) (JP) 2007-12-20 US disclosed
US-20070293510-A1 Thiadiazole compounds and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED ( A JAPANESE CORPORATION) (JP) 2007-12-20 US disclosed
US-20070293510-A1 Thiadiazole compounds and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED ( A JAPANESE CORPORATION) (JP) 2007-12-20 US disclosed
US-7273879-B2 Thiadiazole compounds and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2007-09-25 US disclosed
US-7273879-B2 Thiadiazole compounds and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2007-09-25 US disclosed
US-7273879-B2 Thiadiazole compounds and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2007-09-25 US disclosed
US-20050215578-A1 Thiadiazole compounds and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2005-09-29 US disclosed
EP-1475374-A1 THIADIAZOLE COMPOUNDS AND USE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2004-11-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050215578-A1 Thiadiazole compounds and use thereof C5, C3AR1, TH ALOX15 940/4885RAB9A 1998/4885SMN1; SMN2 3880/4885
US-20070293510-A1 Thiadiazole compounds and use thereof C5, C3AR1, TH ALOX15 977/4885RAB9A 2211/4885SMN1; SMN2 3891/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.